Ikonisys Closes Capital Increase Through a Private Placement to Further Accelerate Its Commercial Development
Summary
Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer"), today announces that it raised 150k, by way of a private placement with a private investor, in order to strengthen its financial resources and further accelerate its development.The net proceeds of this issue, amounting to 150k, should provide the Issuer with additional resources to support its commercial development, by financing its working capital needs and extend its financial visibility. The settlement-delivery of the new shares will take place on June 4, 2024.The Capital Increase did not require the approval of a notice ("prospectus") by the Autorit\xe9 des march\xe9s financiers (the "AMF").The Issuer has issued a total of 100,000 new ordinary shares, with a par value of 0.5 each, to the investor, pursuant to article L. 411-2 1\xb0 of the French Monetary and Financial Code, in accordance with the 8th resolution passed by its Annual General Meeting on June 28, 2023.The issuance price of the new shares issued under the Capital Increase, equal to 1.5 per share, represents a premium of approximately 3% on the Ikonisys share price at the close of May 31, 2024.Impact of the transaction in terms of liquidity risk management and financing horizonAs at June 30, 2023, and as mentioned in the half-year financial statements published on October 31, 2023, the Issuers consolidated cash position amounted to 66k.Thanks to the Capital Increase and the previously secured financing facility, the Company will be in a position to meet its financing needs for more than 12 months._________________1 Ikonisys to Acquire Hospitex International and Become an Integrated Cancer Diagnostic Leader, November 30, 2023Impact of the Capital Increase on a shareholder holding 1% of the capitalOn the basis of the 10,451,424 shares outstanding, the impact on the shareholding of a shareholder holding 1% of the Issuers capital prior to the transaction is as follows:Capital breakdown before and after completion of the Capital IncreaseDetailed information about the Issuer, including its business, financial information, results, outlook and related risk factors, is contained in the 2022 annual financial report for the financial year ended December 31, 2022, published on April 29, 2023, and in the half-year report 2023, published on October 31, 2023. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).For further information, please go to www.ikonisys-finance.comThis press release contains forward-looking statements about the Companys prospects and development. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation.